Brief Title
A Trial of Intravenous Denileukin Diftitox Plus Subcutaneous Pegylated IFNα-2A in Stage III or IV Ovarian Cancer
Official Title
A Phase II Trial of Intravenous Denileukin Diftitox Plus Subcutaneous Pegylated IFNα-2a to Treat Epithelial Ovarian Cancer FIGO Stage III or Stage IV, Extraovarian Peritoneal or Fallopian Tube Carcinoma or Ineligible for First-Line Therapy
Brief Summary
This study will test the hypothesis that adding pegylated IFN (IFN)a-2b to denileukin
diftitox improves the potential of denileukin diftitox alone to deplete regulatory T cells
(Tregs) and will thereby boost tumor immunity in patients with advanced-stage epithelial
ovarian cancers, enhancing treatment efficacy.
Detailed Description
The aims of this study are to:
- Assess the efficacy of adding pegylated IFN-α2b to denileukin diftitox to treat selected
advanced-stage epithelial ovarian cancers
- Test the immune-modulating effects of adding pegylated IFN-α2b to denileukin diftitox in
ovarian cancer patients and relate them to clinical efficacy
- Identify any toxicity associated with pegylated IFN-α2b plus denileukin diftitox
treatment in these patients
- Identify practical means to dose the immunomodulating agents denileukin diftitox and
pegylated IFN-α2b based on immunopharmacodynamic metrics
Study Phase
Phase 2
Study Type
Interventional
Primary Outcome
Clinical Response Rate
Condition
Epithelial Ovarian Cancer
Intervention
Denileukin Diftitox/SC Pegylated IFNα-2a
Study Arms / Comparison Groups
Denileukin Diftitox/SC Pegylated IFNα-2A
Description: Administration of Denileukin Diftitox Plus Subcutaneous Pegylated IFNα-2A
Publications
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
Recruitment Information
Recruitment Status
Drug
Estimated Enrollment
2
Start Date
June 2009
Completion Date
June 2011
Primary Completion Date
June 2011
Eligibility Criteria
Inclusion Criteria:
- Able to provide informed consent
- Not on immune-modulating drugs, except those used as denileukin diftitox
premedication, unless the principal investigator grants an exception (which exception
must be documented in writing)
- Histologically proven epithelial (non-germ cell, non-stromal cell) cancer of the
ovaries, fallopian tubes or extraovarian peritoneal carcinoma. Clinical recurrence
without documented pathology is acceptable
- FIGO stage III or IV with failed prior first-line therapy, or ineligible for or
intolerant of such therapy
- Measurable disease as defined in section 6 within 30 days of study enrollment
- Blood hemoglobin ≥ 8.5 gm/dl within 7 days of study enrollment
- Absolute neutrophil count ≥ 750/mm3 within 7 days of study enrollment
- Platelet count ≥ 40,000/mm3 within 7 days of study enrollment
- SGOT (serum glutamic oxaloacetic transaminase) ≤10 x upper limit of normal within 7
days of study enrollment
- Normal TSH (thyroid-stimulating hormone ) within 30 days of study enrollment
- No chemotherapy in the 14 days prior or radiation therapy in the thirty days prior to
initiation of treatment on this study
- No other concurrent chemotherapy, surgery or radiation therapy during this protocol
except surgery or radiation therapy to control symptoms with concurrence of the
principal investigator
- No contraindication to any study treatment
- No active major medical problems, including untreated or uncontrolled infections
- Beck Depression Index ≥15 within 30 days of study enrollment
- If of reproductive potential, a negative urine pregnancy test within 3 days of study
enrollment, and agreement to use adequate contraception. Pregnancy testing will
continue monthly while on treatment unless the subject is no longer able to become
pregnant or there is sufficient justification otherwise
- Not breast feeding
- Life expectancy ≥ six months
- ECOG (Eastern Cooperative Oncology Group) performance status ≤ 2
- Serum albumin ≥ 1.8 gm/dl
- Age ≥ 18 years
- Acceptable baseline retinal examination within 30 days of study enrollment
- No active substance abuse in the prior 6 months
- Patients failing single agent denileukin diftitox in the ongoing trial "A Phase II
Trial of Intravenous Ontak to Treat Epithelial Ovarian Cancer FIGO Stage III or Stage
IV, or Extraovarian Peritoneal Carcinoma, Failing or Ineligible for First-Line
Therapy" are eligible for this trial provided that three or more weeks have elapsed
since their last denileukin diftitox infusion and they meet all eligibility criteria
and successfully undergo all screening examinations for this trial.
Exclusion Criteria:
- Unable to tolerate phlebotomy
- Germ cell or stromal cell cancers of the ovaries, or other currently uncured cancer
- Active autoimmune disease including systemic lupus erythematosus, psoriasis, or
inflammatory bowel disease that is not medically controlled
- Autoimmune hepatitis, whether medically controlled or not
- Contraindication to any study drug
- Known hypersensitivity to denileukin diftitox, pegylated IFN-α2a or any of their
components or excipients
- Current pregnancy or breast feeding
- Inability to document adequate contraception if a female of reproductive potential
- On other immune-modulating drugs, except denileukin diftitox premedications or those
approved by the principal investigator
- Chemotherapy within 14 days or radiation therapy within the thirty days prior to
initiation of study treatment
- Life expectancy less than six months
- Serum albumin < 1.8 gm/dl
- Blood hemoglobin < 8.5 gm/dl
- ECOG performance status> 2
- Symptomatic coronary artery disease (including uncontrolled angina, congestive heart
failure, and the like)
- Uncontrolled hypertension (diastolic BP consistently >100 mm Hg or systolic BP
consistently >160 mm Hg on a regular basis)
- Uncontrolled, symptomatic cardiac arrhythmia
- Retinopathy associated with significant visual impairment
- Beck Depression Index >15
- Active substance abuse in the prior 6 months
Gender
Female
Ages
18 Years - N/A
Accepts Healthy Volunteers
No
Contacts
Tyler Curiel, MD, ,
Location Countries
United States
Location Countries
United States
Administrative Informations
NCT ID
NCT01773889
Organization ID
HSC20090233H
Secondary IDs
OCR 09-01
Responsible Party
Sponsor
Study Sponsor
The University of Texas Health Science Center at San Antonio
Study Sponsor
Tyler Curiel, MD, Principal Investigator, The University of Texas Health Science Center at San Antonio
Verification Date
May 2013